Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06146608 · ClinicalTrials.gov registry record
Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption
A clinical trial of Anemia, Iron Deficiency and Iron Overload, sponsored by Cornell University.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT06146608: Recruiting study of Anemia, Iron Deficiency and Iron Overload, sponsored by Cornell University.
NCT06146608 is a study of Anemia, Iron Deficiency and Iron Overload that is actively recruiting participants, run by Cornell University. The registered enrollment target is 120 participants, below the 176-participant average among 8 other Anemia, Iron Deficiency trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06146608, a study of Anemia, Iron Deficiency and Iron Overload, is actively recruiting participants, sponsored by Cornell University.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The FeMicrobiome study will evaluate gut microbiome features and their relationships with dietary iron absorption in healthy adults. The investigators hypothesize that (1) the gut microbiota can be shaped by the heme and non-heme Fe content of the diet and that (2) this will influence individual variation in dietary Fe absorption.
Primary Outcome
Percent non-heme iron absorption will be determined by red blood cell iron incorporation of stable 57Fe
Conditions Studied
Study Locations (1)
New York
- Cornell University - Ithaca
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-01-15 |
| Est. Completion | 2026-01-14 |
What NCT06146608 shows while recruiting
NCT06146608 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 8 other Anemia, Iron Deficiency trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with Anemia, Iron Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT06146608 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06146608 about?
NCT06146608 is a clinical study titled "Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption". The FeMicrobiome study will evaluate gut microbiome features and their relationships with dietary iron absorption in healthy adults. The investigators hypothesize that (1) the gut microbiota can be shaped by the heme and non-heme Fe content of the diet and that (2) this will influence individual var...
What is the current status of trial NCT06146608?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2023-01-15. Estimated completion is 2026-01-14.
What conditions does trial NCT06146608 study?
This clinical trial studies the following conditions: Anemia, Iron Deficiency, Iron Overload.
Who is sponsoring clinical trial NCT06146608?
This trial is sponsored by Cornell University, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06146608 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia, Iron Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06146608's enrollment target sits among peer trials
120 4th of 8 higher than 4 of 8 other Anemia, Iron Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia, Iron Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Antenatal Support for Iron Deficiency Anemia
RECRUITING · Phase 4
-
Depth of Maximal Ileal Insertion During Retrograde Enteroscopy With TTS Balloon
RECRUITING
-
Iron Deficiency Anemia (IDA) and the Brain
RECRUITING · Phase 4
-
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department
RECRUITING · Phase 3
-
Ethnic Differences in Iron Absorption (FeGenes)
ACTIVE NOT RECRUITING
-
Iron Dosing Pilot Study Using Model Predictive Control
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI